Imaging Liver Metastases with a New Oral Manganese-Based Contrast Agent
Authors:
- Elizaveta ChabanovaECElizaveta Chabanova
- Vibeke LogagerVLVibeke Logager
- Jakob M. MollerJMJakob M. Moller
- Hellen DekkerHDHellen Dekker
- Jelle BarentszJBJelle Barentsz
- Henrik S. ThomsenHTHenrik S. Thomsen
- 1 July 2006
- journal article
- clinical trial
- Published by Elsevier in Academic Radiology
- Vol. 13 (7) , 827-832
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Contrast Agents for MR Imaging of the LiverRadiologic Clinics of North America, 2005
- Detection of Liver Metastases from Adenocarcinoma of the Colon and Pancreas: Comparison of Mangafodipir Trisodium–Enhanced Liver MRI and Whole-Body FDG PETAmerican Journal of Roentgenology, 2005
- Magnetic Resonance Imaging of the Liver: Review of Techniques and Approach to Common DiseasesSeminars in Ultrasound, CT and MRI, 2005
- Safety of MR liver specific contrast mediaEuropean Radiology, 2004
- Detection and characterization of focal hepatic lesions: Mangafodipir vs. Superparamagnetic iron oxide‐enhanced magnetic resonance imagingJournal of Magnetic Resonance Imaging, 2004
- Effect of new manganese contrast agent on tissue intensities in human volunteers: comparison of 0.23, 0.6 and 1.5 T MRI, a part of a phase I trialMagnetic Resonance Materials in Physics, Biology and Medicine, 2004
- Oral manganese for liver imaging at three different field strengths1Academic Radiology, 2004
- Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applicationsEuropean Radiology, 2004
- Increased manganese concentration in the liver after oral intake1Academic Radiology, 2004
- Characterization of Liver Lesions with Mangafodipir Trisodium–enhanced MR Imaging: Multicenter Study Comparing MR and Dual-Phase Spiral CTRadiology, 2002